214 related articles for article (PubMed ID: 17953473)
1. Dose-response characteristics of olmesartan medoxomil and other angiotensin receptor antagonists.
Smith DH
Am J Cardiovasc Drugs; 2007; 7(5):347-56. PubMed ID: 17953473
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of olmesartan medoxomil in patients with mild to moderate essential hypertension: the OLMEBEST Study.
Barrios V; Boccanelli A; Ewald S; Girerd X; Heagerty A; Krzesinski JM; Lins R; Rodicio J; Stefenelli T; Woittiez A; Böhm M
Clin Drug Investig; 2007; 27(8):545-58. PubMed ID: 17638395
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of olmesartan medoxomil and hydrochlorothiazide compared with benazepril and amlodipine besylate.
Kereiakes DJ; Neutel JM; Punzi HA; Xu J; Lipka LJ; Dubiel R
Am J Cardiovasc Drugs; 2007; 7(5):361-72. PubMed ID: 17953475
[TBL] [Abstract][Full Text] [Related]
4. Combination therapy with olmesartan medoxomil and hydrochlorothiazide: secondary analysis of the proportion of patients achieving recommended blood pressure goals from a randomized, double-blind, factorial study.
Chrysant SG; Chavanu KJ; Xu J
Am J Cardiovasc Drugs; 2009; 9(4):241-51. PubMed ID: 19655819
[TBL] [Abstract][Full Text] [Related]
5. A review of olmesartan medoxomil monotherapy: antihypertensive efficacy similar to that of other angiotensin II receptor blocker/hydrochlorothiazide combinations?
Greathouse M
Congest Heart Fail; 2002; 8(6):313-20. PubMed ID: 12461321
[TBL] [Abstract][Full Text] [Related]
6. Olmesartan medoxomil.
Warner GT; Jarvis B
Drugs; 2002; 62(9):1345-53; discussion 1354-6. PubMed ID: 12076183
[TBL] [Abstract][Full Text] [Related]
7. Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan.
Smith DH; Dubiel R; Jones M
Am J Cardiovasc Drugs; 2005; 5(1):41-50. PubMed ID: 15631537
[TBL] [Abstract][Full Text] [Related]
8. Olmesartan medoxomil: an angiotensin II-receptor blocker.
Brousil JA; Burke JM
Clin Ther; 2003 Apr; 25(4):1041-55. PubMed ID: 12809956
[TBL] [Abstract][Full Text] [Related]
9. Olmesartan medoxomil: a review of its use in the management of hypertension.
Scott LJ; McCormack PL
Drugs; 2008; 68(9):1239-72. PubMed ID: 18547134
[TBL] [Abstract][Full Text] [Related]
10. Olmesartan medoxomil: the seventh angiotensin receptor antagonist.
Gardner SF; Franks AM
Ann Pharmacother; 2003 Jan; 37(1):99-105. PubMed ID: 12503943
[TBL] [Abstract][Full Text] [Related]
11. Antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertension.
Chrysant SG; Marbury TC; Robinson TD
J Hum Hypertens; 2003 Jun; 17(6):425-32. PubMed ID: 12764406
[TBL] [Abstract][Full Text] [Related]
12. Olmesartan medoxomil/amlodipine.
Sanford M; Keam SJ
Drugs; 2009; 69(6):717-29. PubMed ID: 19405551
[TBL] [Abstract][Full Text] [Related]
13. Combination therapy for hypertension: focus on high-dose olmesartan medoxomil (40 mg) plus hydrochlorothiazide.
Rump LC; Sellin L
Expert Opin Pharmacother; 2010 Sep; 11(13):2231-42. PubMed ID: 20707758
[TBL] [Abstract][Full Text] [Related]
14. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension.
White WB; Weber MA; Sica D; Bakris GL; Perez A; Cao C; Kupfer S
Hypertension; 2011 Mar; 57(3):413-20. PubMed ID: 21282560
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide.
Chrysant SG; Weber MA; Wang AC; Hinman DJ
Am J Hypertens; 2004 Mar; 17(3):252-9. PubMed ID: 15001200
[TBL] [Abstract][Full Text] [Related]
16. Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil in achieving 24-hour blood pressure reductions and ambulatory blood pressure goals.
Brunner HR; Arakawa K
Clin Drug Investig; 2006; 26(4):185-93. PubMed ID: 17163250
[TBL] [Abstract][Full Text] [Related]
17. Effect of an olmesartan medoxomil-based treatment algorithm on systolic blood pressure in patients with stage 1 or 2 hypertension: a randomized, double-blind, placebo-controlled study.
Kereiakes DJ; Maa JF; Shojaee A; Dubiel R
Am J Cardiovasc Drugs; 2010; 10(4):239-46. PubMed ID: 20653330
[TBL] [Abstract][Full Text] [Related]
18. Olmesartan medoxomil: current status of its use in monotherapy.
Brunner HR
Vasc Health Risk Manag; 2006; 2(4):327-40. PubMed ID: 17323586
[TBL] [Abstract][Full Text] [Related]
19. Clinical and experimental aspects of olmesartan medoxomil, a new angiotensin II receptor antagonist.
Yoshida K; Kohzuki M
Cardiovasc Drug Rev; 2004; 22(4):285-308. PubMed ID: 15592575
[TBL] [Abstract][Full Text] [Related]
20. [Pharmacological profiles and clinical effects of olmesartan medoxomil, a novel angiotensin II receptor blocker].
Sada T; Mizuno M
Nihon Yakurigaku Zasshi; 2004 Oct; 124(4):257-69. PubMed ID: 15467259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
